Almost eight months after the White House first announced it would move from containment to mitigation efforts to stop the spread of the COVID-19 epidemic, the administration is now pinning its hopes on vaccines to inoculate the population and therapies to treat the disease.
Months after announcing it would be working with technology giants Apple and Google on a contact tracing app (and nearly two months after Google and Apple rolled out their exposure notification features) and initiating widespread testing efforts nationwide with the largest national pharmacies (which never received the coordinated support it needed), the administration appears to be giving up on a national effort to stop the spread of the COVID-19 epidemic.
In an interview with CNN's Jake Tapper, White House Chief of Staff Mark Meadows said that the U.S. is "not going to control the pandemic... We are gonna control the fact that we get vaccines, therapeutics and other mitigation."
MEADOWS: We're not going to control the pandemic
TAPPER: Why not?
M: Because it's a contagious virus
T: Why not make efforts to contain it?
M: What we need to do is make sure we have the proper mitigation factors to make sure people don't die pic.twitter.com/0DYgk4rB3T
— Aaron Rupar (@atrupar) October 25, 2020
The admission is a final nail in the coffin for a federal response that could have involved a return to lockdowns to stop the spread of the virus, or national testing and contact tracing and other mitigation measures. Meadows' statement comes as the U.S. experiences a second peak in infection rates. There are now more than 8.1 million cases and over 220,000 deaths since the first confirmed infection on U.S. soil on January 20.
The number of Covid cases, hospitalizations, and deaths is going to continue to grow sharply as we enter the winter; until all of us on our own start taking enough collective action to slow the spread. There is no seasonal backstop, and won’t be any new national policy action. https://t.co/YoCFZkhVSb
— Scott Gottlieb, MD (@ScottGottliebMD) October 23, 2020
Now the focus is all on the vaccines, therapies and treatments being developed by large pharma companies and startups alike that are making their way through the approval processes of regulatory agencies around the world.
The vaccines in phase-three clinical trials
There are currently 12 vaccines in large-scale, late-stage clinical trials around the world, including ones from American companies Novavax, Johnson & Johnson, Moderna Therapeutics and Pfizer, which are recruiting tens of thousands of people in the U.S. and U.K. to volunteer for testing.
In China, the state-run pharmaceutical company Sinopharm has filed its application to China's regulatory commission for the approval of a vaccine and hundreds of thousands of civilians have already been vaccinated under emergency use approvals from the Chinese government, according to a report in The New Yorker. Meanwhile the privately held Chinese pharmaceutical company Sinovac is moving forward with phase-three trials for its own vaccine in Brazil, Bangladesh and Indonesia. Another private Chinese company, CanSino Biologics, developed a vaccine that was already being distributed to members of the Chinese military in late July.
A collaboration in the U.K. between the University of Oxford and European pharmaceutical company AstraZeneca is also recruiting volunteers in Brazil, India, the United Kingdom, the U.S. and South Africa. And, in Australia, the Murdoch Children's Research Institute is trying to see whether a vaccine used to prevent tuberculosis could be used to vaccinate against the coronavirus.
Finally, in Russia, the Gamaleya National Center of Epidemiology and Microbiology in partnership with the state-run Russian Direct Investment Fund has claimed to have developed a vaccine that the country has registered as the first on the market cleared for widespread use. Russia has not published any data from the clinical trials it claims to have conducted to prove the efficacy of the vaccine and the World Health Organization still considers the treatment to be in the first phase of development.
Therapies in phase-three clinical trials
If vaccines can prevent infection, a slew of companies are also working on ways to limit the severity of the disease should someone become infected with Sars-Cov-2, the novel coronavirus that causes COVID-19.
The Milken Institute lists 41 different therapies that have made it through to phase three of their clinical trials (the last phase before approval for widespread delivery).
These therapies come in one of five primary categories: antibody therapies, antivirals, cell-based therapies, RNA-based treatments and repurposing existing treatments that may be in pharmaceutical purgatory.
Antibody therapies use the body's natural defense systems either taken from the blood of people who have recovered from an infection or manufactured in a lab to neutralize the spread of a virus or bacteria. Antivirals, by contrast, stop a virus from spreading by attacking the viruses' ability to replicate. Cell-based therapies are designed to boost the immune system's ability to fight pathogens like viruses or bacteria. Meanwhile, RNA-based treatments are another method to stop the virus from replicating by blocking the construction of viral proteins. Finally, several companies are mining their libraries of old drug compounds to see if any might be candidates for COVID-19 treatments.
So far, only three therapeutics have been approved to treat COVID-19. In the U.K. and Japan dexamethasone has received approvals, while favilavir is being used in China, Italy and Russia; and -- famously thanks to its use by the president -- remdesivir has been approved in the United States, Japan and Australia.
The U.S. is also using convalescent plasma to treat hospitalized patients under emergency use authorizations. And special cases, like the president's, have had access to other experimental treatments like Regeneron's cell therapy under emergency use authorizations.
And there are several U.S.-based startups developing potential COVID-19 therapies in each of these areas.
Adaptive Biotechnologies, Cytovia Therapeutics and SAB Biotherapeutics are all developing antibody treatments. Applied Therapeutics is using an understanding of existing compounds to develop treatments for specific conditions associated with COVID-19. Cellularity has a cell-therapy that could reduce a patient's viral load by stimulating so-called natural killer cells to attack infected cells. Humanigen has developed a new drug that could reduce fatalities in high-risk COVID-19 patients with severe pneumonia. Meanwhile, Partner Therapeutics is working on a drug that could improve lung function in COVID-19 patients -- and potentially boost antibody production against the virus and restore damaged lung cells. Finally, Sarepta Therapeutics has been working with the United States Army Medical Research Institute of Infectious Diseases to find ways for its RNA-based treatment to stop the spread of coronaviruses by attacking the ability for the virus to replicate.
Beyond therapies, startups are finding other ways to play a role in helping the nation address the COVID-19 epidemic.
“At this point the U.S. doesn’t have the best public health system, but at the same time we have best-in-class private companies who can sometimes operate a lot more efficiently than governments can,” Carbon Health chief executive Eren Bali told the audience at TechCrunch's Disrupt 2020 conference. “We also just recently launched a program to help COVID-positive patients get back to health quickly, a rehabilitation program. Because as you know even if you survive it doesn’t mean your body was not affected, there are permanent effects.”
Indeed, the drive for more effective at-home tests and remote treatments for consumers are arguably more important when the federal government refuses to make the prevention of viral spread a priority, because consumers may voluntarily lock down if the government won't.
“This is an opportunity to take a technology that naturally is all about detecting viruses — that’s what CRISPR does in [its native environment] bacteria — and repurposing it to use it as a rapid diagnostic for coronavirus,” said the Nobel Prize-winning co-inventor of some foundational CRISPR gene-editing technology, Jennifer Doudna. “We’re finding in the laboratory that that means that you can get a signal faster, and you can also get a signal that is more directly correlated to the level of the virus.”